ОБ ЭТОМ ЭПИЗОДЕ
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
английский
США
РАСШИФРОВКА 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ПОИСК ПРОШЛЫХ ЭПИЗОДОВ
Искать прошлые эпизоды Pathfinders in Biopharma.
ДРУГИЕ ЭПИЗОДЫ В ЭТОМ ПОДКАсте
Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.
Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all…
Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape.
www.ocutx.com
Pravin U. Dugel, MD Biography
Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and …
Отказ от ответственности: Подкаст и иллюстрации, встроенные в эту страницу, взяты из RBC Capital Markets, который является собственностью его владельца и не связан или не одобрен Listen Notes, Inc.
ИЗМЕНИТЬ
Спасибо, что помогаете поддерживать базу подкастов актуальной.
